Drugs for the treatment of CHF, HTN, angina and HLD Flashcards
Digoxin MOA
Inhibits the Na/K ATPase at the potassium binding site (less Na so more Ca) to increase contractility. Reduces HR (decreases SNS tone which prevails in CHF). Increases CO in the failing heart.
Digoxin Main Effect
Positive Inotrope for CHF.
Digoxin Side Effects
Narrow margin of safety. Earliest sign of toxicity is GI upset. CNS effects. Cardiac arrhythmias are the most common and most dangerous: Bigeminy.
Treatment of Digoxin toxicity
Discontinue or reduce amount of digoxin. Moderate toxicity: oral/IV potassium. Severe: Digitalis immune Fab with potassium.
increased Digoxin toxicity
Hypokalemia (loops/thiazides and diarrhea)
Phosphodiesterase Inhibitors MOA
Inhibit cAMP phosphodiesterase to increase cAMP leading to more calcium influx and stronger contraction with significant vasodilation.
Inamrinone
Phosphodiesterase Inhibitor
Milrinone
Phosphodiesterase Inhibitor
Phosphodiesterase Inhibitors Indication
Acute heart failure. Increases CO as a last ditch effeort
Drugs that Reduce CHF mortality
Aldosterone antagonists, beta blockers, ACE-I and ARBs
Dopamine Indications
Severe refractory CHF. At a moderate dose will bind beta 1 receptors in the heart. IV only.
Dobutamine (Dobutrex)
Beta-1 agonist that is a positive inotrope (less tachycardia). Decreases filling pressure and increases oxygen consumption. IV only.
Diuretics Used for CHF
Spironolactone and Eplerenone (aldosterone antagonists). Reduces mortality rate in CHF. Decreases venous pressure to decrease edema and cardiac size.
DOC for CHF
ACE inhibitors (-prils). Reduces mortality.
ACE inhibitors MOA
“-prils” Inhibits ACE to stop conversion of angiotensin I to angiotensin II. Decreases afterload (Less angio II induced vasoconstriction) and decreases preload (less aldosterone) decreases cardiac remodeling.
ACE inhibitor Side Effects
Dry cough and angioedema due to increases in bradykinin.
Angiotensin II receptor blockers (ARB) MOA
“-sartans” Block the binding of angiotensin II to the AT1 receptor.
Beta-Blockers and CHF
Decreases renin secretion, attenuates catecholamine effects, decreases HR, stops cardiac remodeling. Decreases mortality. Only use in the early stages due to negative inotropic effect. Carvedilol and metoprolol.
Vasodilators used for CHF
Sodium nitroprusside (nitropress), Isosorbide dinitrate, hydralazine (SLE causing). Decrease preload, afterload and cardiac remodeling.
DOC for HTN
Thiazides
Adverse effects of thiazides
Reduced glucose tolerance
Thiazide contraindication
Diabetes
Clonidine
Centrally acting sympatholytic.
Methyldopa
Centrally acting sympatholytic
Centrally acting sympatholytic MOA
Bind alpha 2 adrenergic receptors to decrease neurotransmitter release and decrease peripheral SNS activity.
Centrally acting sympatholytic Effects
Decrease SNS outflow
DOC for HTN in pregnancy
Methyldopa
Methyldopa Side effects
Hemolytic anemia
Prazosin
Alpha-adrenergic Antagonist
Terazosin
Alpha-adrenergic Antagonist
Doxazosin
Alpha-adrenergic Antagonist
Alpha-adrenergic Antagonist Indications
Useful for treating HTN in men with BPH
Alpha-adrenergic Antagonist Side Effects
First dose phenomenon
Timolol
Non-selective Beta Blocker
Propanolol
Non-selective Beta Blocker
Nadolol
Non-selective Beta Blocker
Metoprolol
Beta 1 blocker
Atenolol
Beta 1 blocker
Nebivolol
Beta 1 blocker
Acebutolol
Beta 1 blocker
Beta Blocker effects
Decrease CO, renin secretion and SNS tone.
Beta Blocker Indications
Reduces mortality in CHF. Angina, Post-MI, Migraines.
Beta Blocker side effects
Blocks insulin release and inhibits recovery from hypoglycemia.
Beta Blocker contraindications
DM, asthma, heart block and end stage CHF